The Food and Drug Administration (FDA) has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for specific high-risk populations, the company announced Saturday. This marks a ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

FDA approved mNEXSPIKE for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor, in late May.

This is the same limited use the FDA set in licensing the Novavax COVID-19 vaccine last month. This fall, Moderna anticipates offering both Spikevax and mNexspike as COVID-19 vaccines.

The main side effects of mNEXSPIKE were injection site pain, fatigue, headache and muscle pain, Moderna said in its press release. This story first appeared on NBCNews.com.

Along with the recent approval of Moderna's next-generation covid vaccine, mNexspike, we think this puts Moderna in a good position to file for approval of both the influenza vaccine and a ...